Evaluation of the effects of misoprostol and letrozole in therapeutic abortio

Phase 3

Recruiting

• Conditions: medical abortion.; Medical abortion; 000-008

• Registration Number: IRCT20200217046521N1
• Lead Sponsor: Dezfoul University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 75

Inclusion Criteria

Hemoglobin level greater than 10 gr / l
Diastolic pressure less than 95 mmhg
Serum hcg level less than 3000 iu / l
Gestational age less than 14 weeks

Exclusion Criteria

Use of abortion drugs in the last three months
itching during pregnancy
Existence of adrenal disorders
Porphyria, steroid-related cancer, acute or chronic liver disease or thromboembolism
History of chronic lung diseases such as asthma, bronchitis, bronchiectasis
known allergy to letrozole or misoprostol
Breast feeding
Multipfetal pregnancy
More than two previous cesarean sections
uterine surgery and myomectomy
contraindications to the letrozol and mosoprostol
Existence of intrauterine devices (IUD)
Uncontrolled seizures
Coagulation disorder or use of anticoagulants
Active liver disease, cardiovascular disease
Adrenal disease
Consumption of glucocorticoids

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fetus abortion. Timepoint: Before and after abortion. Method of measurement: Eight hours after the intervention, and every twenty-four hours up to three days if the abortion doesn't occur.